ABEIXI™
生化试剂
| SP-MHCI-0193-2 | Antigen Peptide Human CMV UL40 – HLA-E*01:01 (VMAPRTLIL) |
| SP-MHCI-0193-3 | Antigen Peptide Human CMV UL40 – HLA-E*01:01 (VMAPRTLIL) |
| SP-MHCI-0194-2 | Antigen Peptide Human CMV pp65 – HLA-C*06:02 (TRATKMQVI) |
| SP-MHCI-0194-3 | Antigen Peptide Human CMV pp65 – HLA-C*06:02 (TRATKMQVI) |
| SP-MHCI-0195-2 | Antigen Peptide Human CMV pp65 – HLA-B*40:01 (HERNGFTVL) |
| SP-MHCI-0195-3 | Antigen Peptide Human CMV pp65 – HLA-B*40:01 (HERNGFTVL) |
| SP-MHCI-0196-2 | Antigen Peptide Human CMV pp65 – HLA-DRB1*11:01 (EHPTFTSQYRIQGKL) |
| SP-MHCI-0196-3 | Antigen Peptide Human CMV pp65 – HLA-DRB1*11:01 (EHPTFTSQYRIQGKL) |
| SP-MHCI-0197-2 | Antigen Peptide Human CMV pp65 – HLA-A*01:01 (SEHPTFTSQY) |
| SP-MHCI-0197-3 | Antigen Peptide Human CMV pp65 – HLA-A*01:01 (SEHPTFTSQY) |
| SP-MHCI-0198-2 | Antigen Peptide Human CMV pp65 – HLA-A*33:03 (SVNVHNPTGR) |
| SP-MHCI-0198-3 | Antigen Peptide Human CMV pp65 – HLA-A*33:03 (SVNVHNPTGR) |
| SP-MHCI-0199-2 | Antigen Peptide Human CMV pp150 – HLA-A*03:01 (TTVYPPSSTAK) |
| SP-MHCI-0199-3 | Antigen Peptide Human CMV pp150 – HLA-A*03:01 (TTVYPPSSTAK) |
| SP-MHCI-0200-2 | Antigen Peptide Human CMV UL138 – HLA-B*35:01 (LPLNVGLPIIGVM) |
| SP-MHCI-0200-3 | Antigen Peptide Human CMV UL138 – HLA-B*35:01 (LPLNVGLPIIGVM) |
| SP-MHCI-0201-2 | Antigen Peptide Human CMV IE1 – HLA-C*07:02 (CRVLCCYVL) |
| SP-MHCI-0201-3 | Antigen Peptide Human CMV IE1 – HLA-C*07:02 (CRVLCCYVL) |
| SP-MHCI-0202-2 | Antigen Peptide Human CMV DBP – HLA-DR3 (PYAVAFQPLLAYAY) |
| SP-MHCI-0202-3 | Antigen Peptide Human CMV DBP – HLA-DR3 (PYAVAFQPLLAYAY) |
| SP-MHCI-0203-2 | Antigen Peptide Human CMV IE1 (R201K) – HLA-B*08:01 (ELKRKMMYM) |
| SP-MHCI-0203-3 | Antigen Peptide Human CMV IE1 (R201K) – HLA-B*08:01 (ELKRKMMYM) |
| SP-MHCI-0204-2 | Antigen Peptide Human CMV IE1 (R201K, M205I) – HLA-B*18:01 (ELKRKMIY) |
| SP-MHCI-0204-3 | Antigen Peptide Human CMV IE1 (R201K, M205I) – HLA-B*18:01 (ELKRKMIY) |
| SP-MHCI-0205-2 | Antigen Peptide Human CMV pp65 – HLA-B*44:02 (EFFWDANDIY) |
| SP-MHCI-0205-3 | Antigen Peptide Human CMV pp65 – HLA-B*44:02 (EFFWDANDIY) |
| SP-MHCI-0206-2 | Antigen Peptide Human CMV IE1 – HLA-B*18 (SDEEEAIVAYTL) |
| SP-MHCI-0206-3 | Antigen Peptide Human CMV IE1 – HLA-B*18 (SDEEEAIVAYTL) |
| SP-MHCI-0207-2 | Antigen Peptide Human CMV pp65 – HLA-A*01:01 (YSEHPTFTSQY) |
| SP-MHCI-0207-3 | Antigen Peptide Human CMV pp65 – HLA-A*01:01 (YSEHPTFTSQY) |
| SP-MHCI-0208-2 | Antigen Peptide CXB4 Polyprotein – HLA-DQB1*03:02 (LRTNNSATIVMPYINSVPMD) |
| SP-MHCI-0208-3 | Antigen Peptide CXB4 Polyprotein – HLA-DQB1*03:02 (LRTNNSATIVMPYINSVPMD) |
| SP-MHCI-0209-2 | Antigen Peptide CXB4 Polyprotein – HLA-A*02:01 (EVKEKHEFL) |
| SP-MHCI-0209-3 | Antigen Peptide CXB4 Polyprotein – HLA-A*02:01 (EVKEKHEFL) |
| SP-MHCI-0210-2 | Antigen Peptide EBV BALF5 – HLA-DRB5*01:01 (TGGVYHFVKKHVHES) |
| SP-MHCI-0210-3 | Antigen Peptide EBV BALF5 – HLA-DRB5*01:01 (TGGVYHFVKKHVHES) |
| SP-MHCI-0211-2 | Antigen Peptide EBV EBNA1 – HLA-B*35:01 (HPVGEADYF) |
| SP-MHCI-0211-3 | Antigen Peptide EBV EBNA1 – HLA-B*35:01 (HPVGEADYF) |
| SP-MHCI-0212-2 | Antigen Peptide EBV EBNA1 – HLA-DRB1*04:01 (EYHQEGGPDG) |
| SP-MHCI-0212-3 | Antigen Peptide EBV EBNA1 – HLA-DRB1*04:01 (EYHQEGGPDG) |
| SP-MHCI-0213-2 | Antigen Peptide EBV EBNA1 – HLA-DR1 (TSLYNLRRGTALAI) |
| SP-MHCI-0213-3 | Antigen Peptide EBV EBNA1 – HLA-DR1 (TSLYNLRRGTALAI) |
| SP-MHCI-0214-2 | Antigen Peptide EBV EBNA3B – HLA-B*15:01 (GQGGSPTAM) |
| SP-MHCI-0214-3 | Antigen Peptide EBV EBNA3B – HLA-B*15:01 (GQGGSPTAM) |
| SP-MHCI-0215-2 | Antigen Peptide EBV EBNA2 – HLA-DRB1*03:01 (PAQPPPGVINDQQLHHLPSG) |
| SP-MHCI-0215-3 | Antigen Peptide EBV EBNA2 – HLA-DRB1*03:01 (PAQPPPGVINDQQLHHLPSG) |
| SP-MHCI-0216-2 | Antigen Peptide EBV EBNA3C – HLA-DQB1*05:01 (SDDELPYIDPNMEPV) |
| SP-MHCI-0216-3 | Antigen Peptide EBV EBNA3C – HLA-DQB1*05:01 (SDDELPYIDPNMEPV) |
| SP-MHCI-0217-2 | Antigen Peptide EBV EBNA3C – HLA-DRB1*01:01 (PAPQAPYQGYQEPPAPQAPY) |
| SP-MHCI-0217-3 | Antigen Peptide EBV EBNA3C – HLA-DRB1*01:01 (PAPQAPYQGYQEPPAPQAPY) |
| SP-MHCI-0218-2 | Antigen Peptide EBV EBNA3C – HLA-B*37:01 (LDFVRFMGV) |
| SP-MHCI-0218-3 | Antigen Peptide EBV EBNA3C – HLA-B*37:01 (LDFVRFMGV) |
| SP-MHCI-0219-2 | Antigen Peptide EBV LMP1 – HLA-B*57:01 (IALYLQQNW) |
| SP-MHCI-0219-3 | Antigen Peptide EBV LMP1 – HLA-B*57:01 (IALYLQQNW) |
| SP-MHCI-0220-2 | Antigen Peptide EBV LMP2 – HLA-B*27:05 (RRRWRRLTV) |
| SP-MHCI-0220-3 | Antigen Peptide EBV LMP2 – HLA-B*27:05 (RRRWRRLTV) |
| SP-MHCI-0221-2 | Antigen Peptide EBV LMP2 – HLA-B*40:01 (IEDPPFNSL) |
| SP-MHCI-0221-3 | Antigen Peptide EBV LMP2 – HLA-B*40:01 (IEDPPFNSL) |
| SP-MHCI-0222-2 | Antigen Peptide EBV BZLF1 – HLA-B*18:01 (EECDSELEIKRY) |
| SP-MHCI-0222-3 | Antigen Peptide EBV BZLF1 – HLA-B*18:01 (EECDSELEIKRY) |
| SP-MHCI-0223-2 | Antigen Peptide EBV BZLF1 – HLA-B*40:02 (SENDRLRLL) |
| SP-MHCI-0223-3 | Antigen Peptide EBV BZLF1 – HLA-B*40:02 (SENDRLRLL) |
| SP-MHCI-0224-2 | Antigen Peptide EBV BMRF1 – HLA-B*39:06 (YRSGIIAVV) |
| SP-MHCI-0224-3 | Antigen Peptide EBV BMRF1 – HLA-B*39:06 (YRSGIIAVV) |
| SP-MHCI-0225-2 | Antigen Peptide EBV EBNA1 – HLA-C*03:04 (FVYGGSKTSL) |
| SP-MHCI-0225-3 | Antigen Peptide EBV EBNA1 – HLA-C*03:04 (FVYGGSKTSL) |
| SP-MHCI-0226-2 | Antigen Peptide EBV BRLF1 – HLA-A*03:01 (RVRAYTYSK) |
| SP-MHCI-0226-3 | Antigen Peptide EBV BRLF1 – HLA-A*03:01 (RVRAYTYSK) |
| SP-MHCI-0227-2 | Antigen Peptide EBV BRLF1 – HLA-A*11:01 (ATIGTAMYK) |
| SP-MHCI-0227-3 | Antigen Peptide EBV BRLF1 – HLA-A*11:01 (ATIGTAMYK) |
| SP-MHCI-0228-2 | Antigen Peptide EBV EBNA3A – HLA-A*02:01 (QAKWRLQTL) |
| SP-MHCI-0228-3 | Antigen Peptide EBV EBNA3A – HLA-A*02:01 (QAKWRLQTL) |
| SP-MHCI-0229-2 | Antigen Peptide EBV EBNA3C – HLA-B*27:05 (RRIYDLIEL) |
| SP-MHCI-0229-3 | Antigen Peptide EBV EBNA3C – HLA-B*27:05 (RRIYDLIEL) |
| SP-MHCI-0230-2 | Antigen Peptide EBV EBNA3C – HLA-B*44:05 (EENLLDFVRF) |
| SP-MHCI-0230-3 | Antigen Peptide EBV EBNA3C – HLA-B*44:05 (EENLLDFVRF) |
| SP-MHCI-0231-2 | Antigen Peptide HAdV-5 Hexon – HLA-A*02:01 (LLYANSAHAL) |
| SP-MHCI-0231-3 | Antigen Peptide HAdV-5 Hexon – HLA-A*02:01 (LLYANSAHAL) |
| SP-MHCI-0232-2 | Antigen Peptide HAdV-5 Hexon – HLA-DPB1*04:01 (DEPTLLYVLFEVFDV) |
| SP-MHCI-0232-3 | Antigen Peptide HAdV-5 Hexon – HLA-DPB1*04:01 (DEPTLLYVLFEVFDV) |
| SP-MHCI-0233-2 | Antigen Peptide HAdV-5 Hexon – HLA-A*01:01 (LTDLGQNLLY) |
| SP-MHCI-0233-3 | Antigen Peptide HAdV-5 Hexon – HLA-A*01:01 (LTDLGQNLLY) |
| SP-MHCI-0234-2 | Antigen Peptide HAdV-5 Hexon – HLA-A*03:01 (GQQSMPNRPNYIAFR) |
| SP-MHCI-0234-3 | Antigen Peptide HAdV-5 Hexon – HLA-A*03:01 (GQQSMPNRPNYIAFR) |
| SP-MHCI-0235-2 | Antigen Peptide HAdV-5 Hexon – HLA-DPB1*02:01 (GTFYLNHTFKKVAIT) |
| SP-MHCI-0235-3 | Antigen Peptide HAdV-5 Hexon – HLA-DPB1*02:01 (GTFYLNHTFKKVAIT) |
| SP-MHCI-0236-2 | Antigen Peptide HAdV-5 Hexon – HLA-DQB1*04:02 (PMDEPTLLYVLFEVF) |
| SP-MHCI-0236-3 | Antigen Peptide HAdV-5 Hexon – HLA-DQB1*04:02 (PMDEPTLLYVLFEVF) |
| SP-MHCI-0237-2 | Antigen Peptide HAdV-5 Hexon – HLA-DR7 (DPYYTYSGSIPYLDG) |
| SP-MHCI-0237-3 | Antigen Peptide HAdV-5 Hexon – HLA-DR7 (DPYYTYSGSIPYLDG) |
| SP-MHCI-0238-2 | Antigen Peptide H. influenzae PAL – HLA-DR9 (EYNIALGQR) |
| SP-MHCI-0238-3 | Antigen Peptide H. influenzae PAL – HLA-DR9 (EYNIALGQR) |
| SP-MHCI-0239-2 | Antigen Peptide H. influenzae PAL – HLA-DR15 (YVQILDAHAAYLNAT) |
| SP-MHCI-0239-3 | Antigen Peptide H. influenzae PAL – HLA-DR15 (YVQILDAHAAYLNAT) |
| SP-MHCI-0240-2 | Antigen Peptide H. pylori HPAA – HLA-DRB1*15:01 (EQILQNQGYKVIS) |
| SP-MHCI-0240-3 | Antigen Peptide H. pylori HPAA – HLA-DRB1*15:01 (EQILQNQGYKVIS) |
| SP-MHCI-0241-2 | Antigen Peptide H. pylori LCTP (E100L) – HLA class II (AAIFLYNLSVKSGYFL) |
| SP-MHCI-0241-3 | Antigen Peptide H. pylori LCTP (E100L) – HLA class II (AAIFLYNLSVKSGYFL) |
| SP-MHCI-0242-2 | Antigen Peptide H. pylori RSMA – HLA class II (EEPYFLISNLPYYIATR) |
| SP-MHCI-0242-3 | Antigen Peptide H. pylori RSMA – HLA class II (EEPYFLISNLPYYIATR) |